Security key
29479A108
Erasca, Inc. - Common Stock, $0.0001 par value per share (ERAS)
CUSIP: 29479A108
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 219,275,999
- Total 13F value
- $815,702,675
- Share change
- +455,965
- Put/Call ratio
- 2.1%
- SEC-reported price per share
- $3.72
- Number of holders
- 153
- Value change
- +$5,117,573
- Number of buys
- 73
- Number of sells
- 64
- Shares outstanding
- 355,466,212
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
153
Top holders
10
ERAS full security history
Ownership snapshot
Full 13F holder table
Erasca, Inc. SEC filings
Erasca, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ERAS - Erasca, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Pub...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 5.3%
13D/G row: Frazier Life Sciences Public Fund, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Public Fund, L.P. leads the comparable SEC ownership view at 5.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Public Fund, L.P.'s linked filing trail.
Comparable ownership
Top 5
Frazier Life Sciences Public Fund...
5.3%
Logos Global Management LP
4.8%
NOVARTIS PHARMA AG
4.4%
Frazier Life Sciences Management,...
6.4%
T. Rowe Price Investment Manageme...
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.3%
|
$21,355,029
15,038,753 shares
|
-$10,702,679 | 30 Jun 2025 |
| Logos Global Management LP |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$33,027,000
15,150,000 shares
|
— | 30 Sep 2025 |
| NOVARTIS PHARMA AG |
13D/G
|
4.4%
|
$17,107,692
12,307,692 shares
|
$0 | 31 Dec 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
6.4%
|
$49,550,170
22,729,436 shares
|
— | 30 Sep 2025 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
5.7%
|
$44,106,000
20,231,906 shares
|
— | 30 Sep 2025 |
| Venrock Adviser, LLC |
13F
Company
|
5%
|
$38,928,441
17,857,083 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
153
Shares
219,275,999
Rows available
153
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
138
Q4 2025 holders
153
Holder diff
15
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|